A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...

ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

A major pooled analysis published in JAMA has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors deliver consistent ...

The use of SGLT2 inhibitors, especially dapagliflozin, can lower adiposopathy parameters in patients with CKD, regardless of ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN DIEGO — Sodium-glucose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors are the preferred for treating comorbid ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...